JPRN-UMIN000015568已完成未知
Phase II study of EGFR-TKI rechallenge with afatinib in advanced NSCLC patients haboring sensitive EGFR mutation without T790M - Phase II study of EGFR-TKI rechallenge with afatinib in advanced NSCLC patients haboring sensitive EGFR mutation without T790M
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)SCLC and sarcoma peoven by rebiopsy 2)Symptomatic brain metastases 3)Leptomeningeal carcinomatosis 4)Active double cancer 5)Severe allergic history 6)Pregnancy 7)Svere complication 8)Indicated for urgent RT 9)Allergic history for afatinib 10)Inadequate patients whom physitians considered
研究者
相似试验
已完成
不适用
Clinical study of a combined use of EGFR-TKI and autologous lymphocyte-activated killer cells (LAK) therapy for advanced non-small cell lung cancer.non-small cell lung cancerJPRN-UMIN000001966Juntendo University, School of Medicine10
进行中（未招募）
不适用
Afatinib translational study in patients with EGFR mutation-positive non-squamous non-small cell lung cancer acquired resistance to osimertinibEGFR mutation-positive non-squamous non-small cell lung cancerJPRN-jRCTs071180013Ryo Toyozawa30
已完成
2 期
Phase II study of gefitinib in patients with EGFR mutation positive- advanced non-small cell lung cancernon-small cell lung cancerJPRN-C000000151West Japan Oncology Group25
已完成
2 期
Multicenter phase II trial of continuous EGFR-TKIs for elderly patients with EGFR sensitive mutation who failed the first EGFR-TKIs treatment for advanced non-small cell lung cancer.JPRN-UMIN000008027ung Oncology Group in Kyushu, Japan (LOGIK)70
尚未招募
2 期
Effectiveness and feasibility of afatinibe in EGFR mutated non-small cell lung cancer patients with postoperative recurrence. -Phase II studyEGFR mutated non-small cell lung cancer patients with postoperative recurrenceJPRN-UMIN000014443Gunma university38